- Meet Consumers/Patients
|FDA Approves Gattex for Treatment of Short Bowel Syndrome in Adults|
In late December, NPS Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Gattex (teduglutide [rDNA origin]) for injection for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex, which will be available in the first quarter of 2013, is a major treatment advance for SBS.
The Oley Foundation encourages research and development of new drugs, products, and services that may improve the health and well-being of our members. We hope this new treatment will reduce the challenges presented by short bowel syndrome/intestinal failure.
For more on Gattex (including the risks), go to gattex.com (an NPS Web site) or watch for an article in an upcoming issue of the Oley newsletter.